INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - FRA:IUI1 - US46120E6023 - Common Stock
480.9 EUR
-9.25 (-1.89%)
IUI1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 60 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 is valued quite expensively, but it does show have an excellent growth rating. This makes IUI1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
IUI1 had positive earnings in each of the past 5 years.
Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
IUI1 has a better Return On Assets (14.19%) than 91.67% of its industry peers.
IUI1 has a Return On Equity of 16.12%. This is amongst the best in the industry. IUI1 outperforms 81.67% of its industry peers.
IUI1's Return On Invested Capital of 11.69% is amongst the best of the industry. IUI1 outperforms 86.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 8.99%.
The last Return On Invested Capital (11.69%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
With an excellent Profit Margin value of 28.58%, IUI1 belongs to the best of the industry, outperforming 96.67% of the companies in the same industry.
IUI1's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 29.44%, IUI1 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
IUI1's Operating Margin has declined in the last couple of years.
The Gross Margin of IUI1 (66.38%) is better than 75.00% of its industry peers.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
IUI1 has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IUI1 has been increased compared to 5 years ago.
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.33
WACC8.78%
2.3 Liquidity
IUI1 has a Current Ratio of 4.97. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IUI1 (4.97) is better than 96.67% of its industry peers.
IUI1 has a Quick Ratio of 4.20. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
IUI1's Quick ratio of 4.20 is amongst the best of the industry. IUI1 outperforms 96.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.12%, which is quite impressive.
IUI1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.47% yearly.
Based on estimates for the next years, IUI1 will show a quite strong growth in Revenue. The Revenue will grow by 14.12% on average per year.
EPS Next Y19.93%
EPS Next 2Y16.17%
EPS Next 3Y15.85%
EPS Next 5Y15.47%
Revenue Next Year21.17%
Revenue Next 2Y18.1%
Revenue Next 3Y16.53%
Revenue Next 5Y14.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 64.90, IUI1 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than 60.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.89. IUI1 is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 56.48, IUI1 can be considered very expensive at the moment.
IUI1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 65.00% of the companies in the same industry.
IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 34.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.9 | ||
| Fwd PE | 56.48 |
4.2 Price Multiples
IUI1's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 65.00% of the companies in the same industry.
IUI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 88.19 | ||
| EV/EBITDA | 56.75 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IUI1 may justify a higher PE ratio.
A more expensive valuation may be justified as IUI1's earnings are expected to grow with 15.85% in the coming years.
PEG (NY)3.26
PEG (5Y)5.65
EPS Next 2Y16.17%
EPS Next 3Y15.85%
5. Dividend
5.1 Amount
No dividends for IUI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IUI1 (11/14/2025, 7:00:00 PM)
480.9
-9.25 (-1.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.66%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap172.39B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts78.54
Price Target522 (8.55%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)1.88%
PT rev (3m)0.68%
EPS NQ rev (1m)3.15%
EPS NQ rev (3m)3.33%
EPS NY rev (1m)5.63%
EPS NY rev (3m)9.92%
Revenue NQ rev (1m)1.61%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)1.17%
Revenue NY rev (3m)1.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 64.9 | ||
| Fwd PE | 56.48 | ||
| P/S | 20.84 | ||
| P/FCF | 88.19 | ||
| P/OCF | 67.66 | ||
| P/B | 11.75 | ||
| P/tB | 12 | ||
| EV/EBITDA | 56.75 |
EPS(TTM)7.41
EY1.54%
EPS(NY)8.51
Fwd EY1.77%
FCF(TTM)5.45
FCFY1.13%
OCF(TTM)7.11
OCFY1.48%
SpS23.08
BVpS40.92
TBVpS40.08
PEG (NY)3.26
PEG (5Y)5.65
Graham Number82.59
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC8.78%
ROIC/WACC1.33
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y19.93%
EPS Next 2Y16.17%
EPS Next 3Y15.85%
EPS Next 5Y15.47%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.17%
Revenue Next 2Y18.1%
Revenue Next 3Y16.53%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.66%
EBIT Next 5Y20.46%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
What is the valuation status of INTUITIVE SURGICAL INC (IUI1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of INTUITIVE SURGICAL INC (IUI1.DE) stock?
The Price/Earnings (PE) ratio for INTUITIVE SURGICAL INC (IUI1.DE) is 64.9 and the Price/Book (PB) ratio is 11.75.
What is the earnings growth outlook for INTUITIVE SURGICAL INC?
The Earnings per Share (EPS) of INTUITIVE SURGICAL INC (IUI1.DE) is expected to grow by 19.93% in the next year.